Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors. However, high excess returns (alpha) are challenging to generate, let alone doubling money. For example, if someone took a bet on the overall economy and bought the broader market index, it would have taken around five to seven years for them to double the investments, as these indices usually take that much time, depending on the economic cycle and market trends. Such gains are never easy to replicate, but certain companies and sectors are better positioned for high growth due to strong fundamentals, innovation, or macroeconomic trends. Investors who can identify these stocks through research and understanding market cycles can generate extra returns. Moreover, specific stocks’ valuation and growth trajectory over the next few years must be precisely analysed to make good returns.
Over the last five years, the stock market has been highly dynamic, reflecting broader economic shifts, interest rate cycles, and technological advancements. While 2023 and 2024 were volatile because of concerns over inflation, the Federal Reserve policy, and geopolitical tensions, 2025 has been equally volatile, with the S&P 500 down 3% and the Nasdaq down around 8% (as of March 27). This volatility makes higher returns riskier.
Nevertheless, market analysts are still optimistic about gains in 2025. In an interview with CNBC on April 1, Chris Hyzy, Merrill and BofA Private Bank CIO, said he would use recent market weakness to increase positions and favour broad market exposure through equal-weighted S&P positions. He identifies financials and consumer discretionary stocks as particularly oversold and attractive. He also believes that certain areas, like software and cybersecurity, could lead the technology sector in share market gains in the coming months. Chris also suggested that while uncertainty may persist into the summer, markets will likely begin pricing in anticipated improvements in economic conditions and corporate earnings later in the year. According to his assessment, the job market remains stable and strong, which would mean a sharp economic downturn is unlikely. He expects the market to experience a “sawtooth bottom” rather than a sharp V-shaped recovery, suggesting that long-term opportunities remain despite persisting volatility.
Fundstrat’s head of research, Tom Lee, stated to CNBC on March 31 that market conditions indicate oversold status and potential bottom formation regardless of ongoing downward trends. Investors maintain their focus on government policies and tariff situations, and their economic impact. According to his estimates, the April 2 tariff updates should also clarify the future of policies and could potentially reduce selling pressure in the market. He also believes that as and when the Federal Reserve communicates further on interest rates, inflation, and other policies, it should provide more direction to investors.
In essence, opportunities could emerge in the near term, and investors should look for better entry points to create positions to generate more substantial returns. But stock selection also remains key. According to Goldman Sachs Asset Management’s March 24 report, Embracing a Broader Equity Landscape, while the technology sector remains a key driver of growth in 2025, the dominance of a few large U.S. tech companies appears to be waning. The authors highlighted that capital is beginning to diversify beyond the Magnificent 7, and many of today’s market leaders may not sustain their positions at the top. This evolving market dynamic presents new opportunities for active investors, particularly in smaller-cap equities, high-quality businesses outside the U.S., and differentiated long-term investment themes. As leadership broadens, they believe this shift could mark the beginning of a more favorable environment for stock selection across the global equity landscape.
In recent months, many analysts and fund managers have favored diversifying towards small- and mid-cap stocks; thus, this space should remain on investors’ radars. At the same time, investors should be aware of the risks involved in high-performing equities.
With those insights, let’s explore the 10 unstoppable stocks that could double your money.
A portfolio manager working diligently on a laptop in a financial trading room to maximize returns for global institutions.
Our Methodology
To identify the unstoppable stocks that could double investors’ money, we used online screeners to compile a list of U.S.-listed companies with a market capitalization exceeding $2 billion and with a greater than 20% return in the last one year. We then applied an additional criterion, considering only those stocks with an expected upside of around 100% or more. From the refined list, we took the top 10 stocks with the highest upside potential and ranked them in ascending order of respective upsides. Additionally, we provided insights into hedge fund sentiment surrounding these stocks, using data from Insider Monkey’s Q4 2024 database.
Note: All pricing data is as of market close on March 27, 2025. 1-year returns are calculated from March 27, 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Unstoppable Stocks That Could Double Your Money
10. Oklo Inc. (NYSE:OKLO)
1-Year Return: 114%
Upside Potential: 99%
Number of Hedge Fund Holders: 27
Oklo Inc. (NYSE:OKLO) is an advanced nuclear reactor company that commercialises small modular reactors (SMRs) for clean and reliable power generation. Company’s flagship product, the Aurora Powerhouse, is a compact fission power system designed to provide carbon-free, baseload energy for industrial, commercial, and microgrid applications.
Oklo is positioned to address power demand needs across multiple end markets, the largest being the data center, which is expected to constitute 30% of total demand growth between 2022 and 2030. The company signed some significant deals in 2024, the largest one was the corporate power agreement with Switch, a pure-play data center company, for 12 gigawatts (GW) of Aurora powerhouse projects through 2044, which brought customer backlog to over 14GW. It also signed an agreement for 500 MW of power with Equinix, another data center company. These deals highlight the company’s long-life reactors and nuclear waste recycling capabilities, positioning it firmly to capitalise on the growing global demand for sustainable and secure energy sources.
Following Oklo Inc.’s (NASDAQ:OKLO) Q4 results, a Craig-Hallum analyst reduced the price target slightly to $43 from $44 while keeping a Buy rating on the stock. The analyst noted that the company is building momentum in 2025. He also believes that progress is expected to increase as the company advances toward deploying its first Aurora Powerhouse at Idaho National Labs and expands its efforts in powering data centers.
Oklo Inc. (NASDAQ:OKLO) shares have risen around 114% over the last year.
9. Avidity Biosciences Inc. (NASDAQ:RNA)
1-Year Return: 32%
Upside Potential: 107%
Number of Hedge Fund Holders: 41
Avidity Biosciences Inc. (NASDAQ:RNA) is a clinical-stage biotech company developing a new type of RNA-based medicines called Antibody Oligonucleotide Conjugates (AOCs). These medicines are designed to deliver genetic treatments directly to the tissues affected by disease, helping target rare genetic conditions that currently have no effective treatments.
The company is trying to revolutionise the delivery of RNA therapeutics, and several of its therapies are under clinical trials. Leerink Partners analyst Joseph Schwartz recently reiterated a Buy rating on Avidity Biosciences Inc. (NASDAQ:RNA) with a $60 price target, citing promising clinical data from the company’s exon skipper candidate, del-zota, for Duchenne muscular dystrophy (DMD). The analyst pointed to encouraging results and believes these improvements could provide meaningful patient clinical benefits.
He also highlighted that Avidity is on track to submit a Biologics License Application (BLA) by the end of 2025, without requiring additional biopsies for new patients. The analyst stated that Avidity’s upcoming program represents their initial commercial entry, while internal activities like manufacturing, along with patient services and market access teams’ development, are already in motion. The small commercial potential of DMD for Avidity does not deter the analyst from seeing this program as essential groundwork for expanding the company’s muscular dystrophy medication development.
8. Applovin Corp. (NASDAQ:APP)
1-Year Return: 280%
Upside Potential: 110%
Number of Hedge Fund Holders: 95
AppLovin Corp. (NASDAQ:APP) operates a software platform that helps mobile app developers increase their business reach using innovative marketing tools, analytics, and monetization components. The company provides services that cover user acquisition initiatives, as well as monetisation features, performance evaluation options, and optimization capabilities. Additionally, the company operates a portfolio of mobile games under its Lion Studios brand.
On March 27, AppLovin’s stock plummeted by 20% following a report by short-seller Muddy Waters. The report accused the company’s e-commerce operations of heavy reliance on retargeting, delivering limited incremental value, as well as violating the terms of service of major digital advertising platforms. The main allegation accused AppLovin of achieving 52% e-commerce conversions from retargeted users when their actual valid sales reached 25% to 35% of the total. AppLovin disputed all accusations by calling them false and misleading information that was targeted to damage their business reputation.
Analysis from Wells Fargo analyst Alec Bonello also confirmed that AppLovin demonstrates excellent e-commerce incrementality according to their data. The research reveals that between 55% and 60% of e-commerce customers make their first purchase at the brand, which opposes claims about targeting existing customers with more than half of the ads. The report also criticised Muddy Waters’ reliance on data from only five customers, arguing that the churn observed is typical of an e-commerce business still in its early stages. The analyst reiterated an Overweight rating on the shares, with a price target set at $538.
Applovin has delivered a remarkable 280% share price return over the past year.
7. Solaris Energy Infrastructure Inc. (NYSE:SEI)
1-Year Return: 170%
Upside Potential: 111%
Number of Hedge Fund Holders: 26
Solaris Energy Infrastructure Inc. (NYSE:SEI) is an energy infrastructure company that provides proppant logistics and last-mile delivery solutions to the North American oil and gas industry. Its integrated systems automate and optimise the supply chain of frac sand, a key material used in hydraulic fracturing.
On February 25, an analyst from Janney Montgomery Scott (JMS) initiated coverage on Solaris Energy Infrastructure Inc. (NYSE:SEI) with a Buy rating and a $57 price target. The analyst noted that following its mid-2024 acquisition of Mobile Energy Rentals LLC, the company now operates a mobile natural gas-fired turbine fleet and is actively expanding to meet growing energy demand. In addition to its Q4 earnings result, Solaris announced its plans to develop a joint venture partnership with its key data center client. Through this collaborative venture Solaris will lease 500 MW of power capacity to support a major data center project. Complete details of the agreement remain undisclosed, but analysts point out that Solaris can gain multiple strategic advantages.
A day before JMS analyst, a Stifel analyst increased his price target to $48 from $42 while maintaining a Buy rating, citing the company’s solid Q4 results. The analyst pointed out that the company has secured significant new orders for its Power Generation assets and signed a long-term contract that exceeds six years, to supply at least 500MW of power to a big data center customer. The analyst remains optimistic about Solaris’ growth potential in the Power segment and has raised estimates accordingly.
Solaris Energy shares have rallied a solid 170% over the last year.
6. Edgewise Therapeutics Inc. (NASDAQ:EWTX)
1-Year Return: 31%
Upside Potential: 113%
Number of Hedge Fund Holders: 49
Edgewise Therapeutics Inc. operates (NASDAQ:EWTX) as a clinical-stage biotech company that creates precise therapeutic solutions for uncommon and critical muscular disorders. The company currently focuses on EDG-5506 as its primary drug candidate because it aims to stop skeletal muscle damage in patients with DMD and BMD.
In addition to EDG-5506, the company is advancing EDG-7500, a cardiovascular candidate for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), expanding its pipeline into another area of significant unmet medical need. Edgewise is committed to discovering and commercialising innovative treatments for muscle-related diseases with limited current options. The company maintains a strong financial position as of Q4 2024, having $470 million in cash while being debt-free, which provides ample funding for its active clinical research programs.
A Scotiabank analyst recently initiated coverage on Edgewise with a price target of $50 along with an Outperform rating because they see promising opportunities ahead in the company’s pipeline. The analyst highlighted promising early clinical data from sevasemten, which is being studied for both Becker and Duchenne muscular dystrophy, and EDG-7500 for cardiomyopathy. He views both programs as potential multi-billion-dollar opportunities and expects positive pipeline momentum to continue as the company progresses towards commercialisation in the near term.
5. ARS Pharmaceuticals Inc. (NASDAQ:SPRY)
1-Year Return: 27%
Upside Potential: 138%
Number of Hedge Fund Holders: 28
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is a biopharmaceutical company focused on developing neffy, a needle-free epinephrine nasal spray designed to treat severe allergic reactions, including anaphylaxis which is known as a fatal condition. Neffy is intended to offer a quick, effective, and user-friendly alternative to traditional epinephrine auto-injectors.
Currently, except for neffy, epinephrine is the only approved in injectable form for the emergency treatment of Type I allergic reactions. With more launches planned, neffy is positioned to be the first needle-free, easy-to-use epinephrine rescue option, giving patients a new, more convenient choice. The company sees a significant market opportunity, with management estimating a potential multi-billion-dollar market ($3 billion prescription segment and up to a $7 billion expansion segment), driven by healthcare providers and patient preference.
On March 7, William Blair analyst Lachlan Hanbury Brown reaffirmed a Buy rating on ARS Pharmaceuticals, noting positive early indicators following neffy’s launch. The company slightly exceeded revenue expectations, reflecting solid initial demand. The analyst also noted progress with healthcare providers, as many have already prescribed neffy and shared encouraging feedback through the neffy experience program. The company also secured favourable insurance coverage with key players like Express Scripts and Cigna, which is expected to accelerate market access faster than planned.
4. Hut 8 Corp. (NASDAQ:HUT)
1-Year Return: 26%
Upside Potential: 141%
Number of Hedge Fund Holders: 34
Hut 8 Corp. (NASDAQ:HUT) is a leading digital asset mining and high-performance computing (HPC) infrastructure company. The company operates large-scale data centers primarily focused on Bitcoin mining and offers cloud and colocation services.
Hut 8 Corp. (NASDAQ:HUT) holds a consensus Buy opinion with a price target of $30, indicating a substantial upside potential of 140%. In line with the rating and reflecting continued confidence in the company’s growth prospects, Canaccord Genuity analyst Joseph Vafi reaffirmed a Buy rating on Hut 8 Corp. (NASDAQ:HUT) in a report dated March 6. The analyst pointed out that Hut 8 has made meaningful progress in expanding its power development pipeline, especially with the recently announced 300MW River Bend data center project.
The analyst also added his view on the recently signed agreement with Bitmain Technologies (a manufacturer of mining servers), which includes an option to purchase ASIC miners. The analyst emphasized that this deal could benefit the company as it not only helps its financial position but will also help it expand its business. Additionally, Hut 8’s substantial Bitcoin holdings provide a strong balance sheet and position the company well to attract future key high-performance computing (HPC) hosting clients.
3. Core Scientific Inc. (NASDAQ:CORZ)
1-Year Return: 134%
Upside Potential: 141%
Number of Hedge Fund Holders: 66
Core Scientific Inc. (NASDAQ:CORZ) operates large-scale, purpose-built facilities for digital asset mining and plays a pivotal role in blockchain infrastructure, software solutions, and related services. The company utilises its extensive fleet of mining machines to generate bitcoin for its portfolio while also providing hosting services for major bitcoin mining clients. Core Scientific’s share price has surged 134% over the past 12 months, marking an impressive performance.
Canaccord Genuity analyst Joseph Vafi reiterated a Buy rating and $17 price target on Core Scientific Inc. (NASDAQ:CORZ) in a March 12 report. The analyst highlighted the positive impact of CoreWeave’s recent $12 billion deal with OpenAI, reinforcing strong demand for AI cloud services. Given CoreWeave is Core Scientific’s largest customer, the partnership is expected to directly support its revenue base. Despite market concerns about potential cuts in Microsoft Corp.’s (NASDAQ:MSFT) data center spending, CoreWeave reported no decline in demand from Microsoft, its key client. Microsoft’s commitment to an $80 billion annual data center budget and CoreWeave’s IPO filing further underpin Core Scientific’s growth prospects.
Core Scientific Inc.’s (NASDAQ:CORZ) stock is down 44% year-to-date, driven by overall market volatility, weaker Q4 results, and changing dynamics in the crypto market. However, the stock still holds a consensus Buy opinion with a 1-year median price target of $19, reflecting a solid 140% upside.
2. Zeta Global Holdings Corp. (NYSE:ZETA)
1-Year Return: 31%
Upside Potential: 157%
Number of Hedge Fund Holders: 39
Zeta Global Holdings Corp. (NYSE:ZETA) operates an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. This approach allows the company to deliver personalized marketing across all addressable channels, including email, social media, web, chat, Connected TV, and video.
In late February, Zeta reported a strong set of Q4 2024 results with revenue and EPS coming ahead of expectations. Revenue for the quarter came in at $315 million, up 50% year-over-year, and FY 2024 revenue crossed $1.0 billion, rising 38%. The company is investing in AI and first-party data, which it expects to help it achieve $2 billion in annual revenue by 2028, per its recently announced Zeta 2028 plan. For FY 2025, revenue is expected to be between $1.24-$1.25 billion, reflecting a strong 23%-24% growth.
Bank of America Securities analyst Koji Ikeda recently reaffirmed a Buy rating on Zeta Global Holdings Corp (ZETA) with a price target of $32, citing the stock’s recent pullback as a good opportunity. After meeting the company’s CFO recently, the analyst became more confident about Zeta’s ability to carry out its strategic plans. He highlighted the company’s cautious 2025 guidance and path to meet longer-term 2028 goals. Zeta plans to grow by boosting the adoption of its integrated solutions, broadening its partner network, and encouraging clients to use more of its products across different channels. The analyst also sees Zeta’s capital deployment, through acquisitions and a share repurchase program, as a strong signal of management’s confidence.
1. Novavax Inc. (NASDAQ:NVAX)
1-Year Return: 50%
Upside Potential: 162%
Number of Hedge Fund Holders: 24
Novavax Inc. (NASDAQ:NVAX) is a clinical-stage biotechnology company. It creates novel vaccines to address various infectious diseases worldwide and employs recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to enhance immune responses.
H.C. Wainwright analyst Vernon Bernardino reaffirmed a Buy rating on Novavax (NASDAQ: NVAX) with a price target of $19, highlighting the company’s strategic shift from COVID-19 vaccine commercialisation to advancing its pipeline. The analyst emphasized Matrix-M adjuvant technology as the primary vital factor because Novavax uses this platform to negotiate lucrative agreements including its recent Sanofi joint venture that may generate $1.2 billion.
The analyst also highlighted the Phase 3 trials of the COVID-19 and influenza combination vaccine that exists within the pipeline alongside early-stage candidates focusing on RSV combinations and shingles. Operations at Novavax are expected to become profitable by 2027, and its existing cash reserves should be able to support business operations for two years. Novavax Inc. (NASDAQ:NVAX) shares have surged around 50% over the past one-year.
While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NVAX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
